Tyelor S Reynolds, Daniel D Hu, Simon D Weaver, Emma C Ronck, Sanket J Mishra, Matthew M Champion, Brian S J Blagg
{"title":"Proteomic Analysis of Hsp90β-Selective Inhibitors Against Triple-Negative Breast Cancer to Gain a Mechanistic Insight.","authors":"Tyelor S Reynolds, Daniel D Hu, Simon D Weaver, Emma C Ronck, Sanket J Mishra, Matthew M Champion, Brian S J Blagg","doi":"10.1016/j.mcpro.2025.101043","DOIUrl":null,"url":null,"abstract":"<p><p>Hsp90 (90 kDa heat shock protein) is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity. This article contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anticancer effects of NDNB1 and NDNB1182 against TNBC. Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, cyclin-dependent kinase 1 (CDK1), and ribosomal protein S9 (RPS9) as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.</p>","PeriodicalId":18712,"journal":{"name":"Molecular & Cellular Proteomics","volume":" ","pages":"101043"},"PeriodicalIF":5.5000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12446539/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular & Cellular Proteomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.mcpro.2025.101043","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0
Abstract
Hsp90 (90 kDa heat shock protein) is a central molecular chaperone responsible for the folding and activation of >400 client proteins, causing it to be a highly sought after drug target for the treatment of cancer. Hsp90 pan-inhibitors have been evaluated in the clinic, but on- and off-target toxicities have limited their development. The emergence of Hsp90β-selective inhibitors has been proposed as a safer therapeutic alternative. However, since they in theory only target a portion of the Hsp90-regulated proteome, a deeper understanding of their mechanism of action and whether they exhibit selectivity for cancer over normal cells has remained uninvestigated. Herein, we show that Hsp90β-selective inhibitors, NDNB1 and NDNB1182, exhibit a moderate selectivity for triple-negative breast cancer (TNBC) over normalized MCF-10A cells in contrast to pan-inhibitors, which do not exhibit a selectivity. This article contains the first proteomic analysis of Hsp90β-selective inhibitors. We have employed a traditional bottom-up LC-MS/MS proteomics approach to explore the potential mechanisms of action underlying the anticancer effects of NDNB1 and NDNB1182 against TNBC. Primarily, inhibition of kinases and associated cell signaling pathways, cell cycle proteins, and DNA repair were notable processes affected by Hsp90β inhibition, to name a few. Further investigation of the impact on Hsp90β interactors allowed a fuller understanding of Hsp90β-dependent processes. We also identified RAD9A, cyclin-dependent kinase 1 (CDK1), and ribosomal protein S9 (RPS9) as potential Hsp90β client substrates. The three example proteins selected exemplify a mechanistic explanation for inhibition of DNA repair (RAD9A), cell cycle (CDK1), and translation (RPS9), shedding some light on some of the implications of Hsp90β inhibition as it pertains to TNBC. Therefore, previously unknown clients, Hsp90β interactors, or Hsp90β-regulated proteins could be determined using the results from this study.
期刊介绍:
The mission of MCP is to foster the development and applications of proteomics in both basic and translational research. MCP will publish manuscripts that report significant new biological or clinical discoveries underpinned by proteomic observations across all kingdoms of life. Manuscripts must define the biological roles played by the proteins investigated or their mechanisms of action.
The journal also emphasizes articles that describe innovative new computational methods and technological advancements that will enable future discoveries. Manuscripts describing such approaches do not have to include a solution to a biological problem, but must demonstrate that the technology works as described, is reproducible and is appropriate to uncover yet unknown protein/proteome function or properties using relevant model systems or publicly available data.
Scope:
-Fundamental studies in biology, including integrative "omics" studies, that provide mechanistic insights
-Novel experimental and computational technologies
-Proteogenomic data integration and analysis that enable greater understanding of physiology and disease processes
-Pathway and network analyses of signaling that focus on the roles of post-translational modifications
-Studies of proteome dynamics and quality controls, and their roles in disease
-Studies of evolutionary processes effecting proteome dynamics, quality and regulation
-Chemical proteomics, including mechanisms of drug action
-Proteomics of the immune system and antigen presentation/recognition
-Microbiome proteomics, host-microbe and host-pathogen interactions, and their roles in health and disease
-Clinical and translational studies of human diseases
-Metabolomics to understand functional connections between genes, proteins and phenotypes